ARS Pharmaceuticals Inc. stock rose Friday as FDA identified deficiencies in rival Aquestive's application, delaying ...
Announces receipt of FDA letter stating it has identified deficiencies that preclude labeling discussions for Anaphylm at this time Receives ...
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) is one of the 12 Stocks that Will Bounce Back According to Wall Street Analysts. On ...
Health system pharmacists and clinicians are monitoring a wave of drug approvals expected throughout 2026, including first-in-class therapies and expanded uses of existing drugs with implications for ...
Announces receipt of FDA letter stating it has identified deficiencies that preclude labeling discussions for Anaphylm at this time Receives confirmation from FDA that Agency's review of Anaphylm NDA ...
Aquestive Therapeutics shares fall after the FDA flags deficiencies in its Anaphylm allergy drug application, raising ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback